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Abstract
Cartilage destruction in osteoarthritis (OA) is thought to be
mediated by two main enzyme families; the matrix
metalloproteinases (MMPs) are responsible for cartilage
collagen breakdown, whereas enzymes from the 'a disintegrin
and metalloproteinase domain with thrombospondin motifs'
(ADAMTS) family mediate cartilage aggrecan loss. Tissue
inhibitors of metalloproteinases (TIMPs) regulate the activity of
these enzymes. Although cartilage destruction in OA might be
driven by the chondrocyte, low-grade synovitis is reported in
patients with all grades of this disease.
Our earlier work profiling these gene families in cartilage
identified a number of genes that are regulated in OA, which are
hence implicated in the disease process. Because the synovium
might contribute to cartilage-matrix destruction in OA, we have
extended the screening in the current study. We have profiled
MMP,  ADAMTS  and  TIMP  genes in both cartilage and
synovium from patients with either OA of the hip or a fracture to
the neck of femur (NOF), giving a more complete picture of
proteolysis in this disease.
The four most significantly upregulated genes (P < 0.0001) in
OA synovium compared to the fractured NOF are MMP28,
ADAMTS16,  ADAMTS17  and  TIMP2. For MMP9,  MMP10,
MMP12,  MMP17, MMP23,  MMP28,  ADAMTS4, and
ADAMTS9, there is a significant correlation between expression
levels in the synovium and cartilage, suggesting similar
mechanisms of regulation. Additionally, we have shown that in
cartilage the median level of steady-state mRNA for MMP13 is
approximately 20-fold higher than MMP28 and approximately
1,500-fold higher than ADAMTS16, with expression of this
latter gene approximately 150-fold higher in synovium than
cartilage.
This study is the most comprehensive analysis of the metzincin
family of proteinases in the joint to date and has identified
several proteinase genes not previously reported to be
expressed or regulated in synovium.
Introduction
Osteoarthritis (OA) is a debilitating degenerative joint disease
characterized by degradation of articular cartilage. Recent sta-
tistics show that approximately 5 million people in the UK suf-
fer from moderate-to-severe OA. These patients are
predominantly older than 45 years of age, with the major mor-
bidity in patients over 60 years of age [1]. Given the current
demographic trend towards an older population, OA, for which
age is an important risk factor, will be an increasing health and
economic burden on society.
The molecular mechanisms underlying cartilage destruction in
OA are poorly understood (reviewed in [2]). Cartilage is made
up of two main extracellular matrix (ECM) macromolecules:
type II collagen and aggrecan, a large aggregating proteogly-
can [3,4]. The former endows the cartilage with its tensile
strength, whereas the latter enables cartilage to resist com-
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pression. Quantitatively, more minor components (e.g. type IX,
XI and VI collagens, biglycan, decorin and cartilage oligomeric
matrix protein) also have important roles in controlling the
supramolecular organization of the matrix [3]. Normal cartilage
ECM is in a state of dynamic equilibrium, with a balance
between synthesis and degradation. For the degradative proc-
ess, there is a balance between proteinases that degrade the
ECM and their inhibitors. In OA, the dogma is that a disruption
of this balance, in favour of proteolysis, leads to pathological
cartilage destruction.
The matrix metalloproteinases (MMPs) are a family of 23
enzymes in humans that facilitate ECM turnover and break-
down in physiology and pathology [5]. The MMP family con-
tains the only mammalian proteinases that can specifically
degrade triple helical collagens at neutral pH. These so-called
'collagenases' specifically cleave a single locus in all three col-
lagen chains at a point three-quarters of the length from the N-
terminus of the molecule. The 'classical' collagenases (MMP-
1, MMP-8 and MMP-13) have differing substrate specificities
for collagens I, II and III, with MMP-13 showing a preference
for type II collagen [6]. More recently, gelatinase A (MMP-2)
and MT1-MMP (MMP-14) have also been shown to make the
specific collagen cleavage, although with less catalytic effi-
ciency than the classical collagenases, at least in vitro [7,8]. A
second group of proteinases has been identified that affect
ECM synthesis and degradation. The 'a disintegrin and metal-
loproteinase domain with thrombospondin motifs' (ADAMTS)
family contains 19 members [9]; these include enzymes
involved in collagen biosynthesis as procollagen propepti-
dases (ADAMTS-2, ADAMTS-3 and ADAMTS-14) [10-13].
Other members of the family are so-called 'aggrecanases'
(ADAMTS-1, ADAMTS-4, ADAMTS-5, ADAMTS-8, ADAMTS-
9 and ADAMTS-15) that degrade the interglobular domain
separating G1 and G2 of aggrecan at a specific Glu373–
Ala374 bond [14-18].
A family of four specific inhibitors, the tissue inhibitors of met-
alloproteinases (TIMPs), has been described [19]. These are
endogenous inhibitors of MMPs and potentially the ADAMTS
family. The ability of the TIMPs to block active MMPs is largely
promiscuous. TIMP-3 seems to be the most potent inhibitor of
the ADAMTS family, with a subnanomolar Ki against ADAMTS-
4 and ADAMTS-5 [20].
Although the dogma has been that OA is a 'noninflammatory'
disease driven by the chondrocyte, there is certainly evidence
for synovial involvement. Low-grade synovitis with thickening
of the lining layer, increased vascularity and inflammatory-cell
infiltration is reported in patients with all grades of OA [21].
This results in the expression of cytokines and proteinases that
could contribute to the pathogenesis of the disease [22].
Arthroscopic studies have also shown that inflammatory
changes in the OA synovium often occur where this tissue is
in contact with cartilage [23,24]. More recent studies using
magnetic resonance imaging (MRI) reinforce the idea that syn-
ovitis is a frequent feature, even of early OA [25].
We recently published a complete expression profile of all
MMPs, the ADAMTS family and the four TIMPs in normal car-
tilage compared with OA cartilage [26]. This identified a
number of genes that are regulated in OA, which are hence
implicated in the disease process. Because the synovium
might contribute to cartilage-matrix destruction in OA, we have
extended the screening in the current study. Hence, we have
profiled MMP, ADAMTS and TIMP genes in both cartilage
and synovium from normal and OA joints, giving a more com-
plete picture of proteolysis in this disease.
Materials and methods
Cartilage samples
Human articular cartilage was obtained from femoral heads of
patients undergoing total-hip-replacement surgery at the Nor-
folk and Norwich University Hospital (Norwich, UK). Samples
from patients with OA (n = 16, of which 7 patients were female
and 9 patients were male; age range, 61–84 years) were com-
pared with cartilage from patients undergoing hip replacement
following fracture to the neck of femur (NOF; n = 24, of which
19 patients were female and 5 patients were male; age range,
52–92 years). OA was diagnosed using the clinical history
and an examination, coupled with X-ray findings; confirmation
of gross pathology was made at time of joint removal. The frac-
ture patients had no known history of joint disease and their
cartilage was free of lesions; 80% of these patients underwent
surgery within 36 hours of fracture. This study was performed
with Ethical Committee approval and all patients provided
informed consent.
Femoral head dissection
Intact femoral heads were washed in sterile PBS. Cartilage
samples were removed from the femoral head using a razor
blade, chopped into 2–5 mm pieces and snap frozen in liquid
nitrogen within 15–30 minutes of surgery. Synovium was
washed in sterile PBS, snap frozen and stored in liquid nitro-
gen.
RNA extraction from articular cartilage
Extractions were performed on the same day or within 24
hours of dissection from the femoral head following the basic
method of Price et al. [27]. Cartilage was weighed and ground
under liquid nitrogen using a freezer mill (SPEX CertiPrep
6750, Glen Creston, Stanmore, Middlesex, UK). TRIzol® rea-
gent (Invitrogen, Paisley, UK) was added immediately to
ground cartilage (1 ml/0.2 g cartilage); the solution was mixed
thoroughly and incubated at room temperature for 5 minutes.
Ground cartilage was pelleted at 9,500 g for 10 minutes at
4°C and the supernatant recovered. To each 0.5 ml of TRIzol®,
300 µl of chloroform was added; the resulting solution was
vortexed for 15 seconds and incubated at room temperature
10 minutes. The TRIzol®/chloroform solution was centrifugedAvailable online http://arthritis-research.com/content/8/4/R124
Page 3 of 10
(page number not for citation purposes)
at 9,500 g for 15 minutes at 4°C. The aqueous layer was
recovered into a fresh tube and mixed with a half volume of
100% ethanol. Using the RNeasy Mini Kit (Qiagen, Crawley,
West Sussex, UK) samples were applied to spin columns and
centrifuged at 9,500 g for 15 seconds at room temperature
and the flow-through discarded. Columns were then washed
and eluted according to the manufacturer's instructions. RNA
samples were quantified using the NanoDrop® spectropho-
tometer (NanoDrop Technologies, Wilmington, Delaware,
USA) and stored at -80°C.
RNA extraction from synovium
To each 100 mg tissue sample, 1 ml of TRIzol® was added; the
solution was homogenized using a TissueLyser (Qiagen,
Crawley, West Sussex, UK). The homogenized sample was
pelleted at 9,500 g for 10 minutes at 4°C and the supernatant
recovered. To each 1 ml of TRIzol®, 400 µl of chloroform was
added; the resulting solution was vortexed for 15 seconds and
incubated at room temperature for 5 minutes. Samples were
centrifuged at 9,500 g for 10 minutes at 4°C. The aqueous
phase was recovered and 250 µl of isopropanol was added.
This was vortexed, as before, and incubated at room tempera-
ture for 10 minutes. The mixture was centrifuged at 9,500 g for
10 minutes at 4°C and the supernatant discarded. The RNA
pellet was washed with 75% ethanol solution and centrifuged
at 9,500 g for 5 minutes at 4°C. The supernatant was dis-
carded, and the pellet was air dried and then suspended in 20
µl of RNAse-free water. The RNA was incubated at 55°C for
10 minutes before storage at -80°C. RNA samples were quan-
tified using the NanoDrop® spectrophotometer (NanoDrop
Technologies, Wilmington, Delaware, USA).
Synthesis of cDNA
cDNA was synthesised from 1 µg of total RNA using Super-
script II reverse transcriptase (Invitrogen, Paisley, UK) and ran-
dom hexamers in a total volume of 20 µl according to the
manufacturer's instructions. cDNA was stored at -20°C until
used in downstream PCR.
Quantitative real-time PCR
Oligonucleotide primers and fluorescent-labelled probes were
designed using Primer Express 1.0 software (Applied Biosys-
tems, Warrington, UK). Sequences for MMP and TIMP prim-
ers and probes are as described in [28] and sequences for
ADAMTS primers and probes are as described in [29]. To
control against amplification of genomic DNA, primers were
Figure 1
Comparative expression of MMP genes in the fractured NOF (filled boxes) compared with OA (open boxes) in hip (a) synovium and (b) cartilage Comparative expression of MMP genes in the fractured NOF (filled boxes) compared with OA (open boxes) in hip (a) synovium and (b) cartilage. 
The expression level of each gene was determined, as described in Materials and methods, and normalized to the level of 18S rRNA gene expres-
sion using ∆CT [CT(target gene) – CT(18S)]. The box-and-whisker plot shows median values, and each section represents a quartile of the data. 
Samples on or below the dotted line have CT(target gene) = 40 and are therefore not detectable (n.d.).Arthritis Research & Therapy    Vol 8 No 4    Davidson et al.
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placed within different exons close to an intron/exon boundary,
with the probe spanning two neighbouring exons where pos-
sible. The BLAST was used to search for all the primer and
probe sequences to ensure gene specificity. The 18S rRNA
gene was used as an endogenous control to normalize for dif-
ferences in the amount of total RNA present in each sample;
the 18S rRNA primers and probe were purchased from
Applied Biosystems (Warrington, UK). Primers for detection of
specific splice variants of MMP28 were as follows:
1. Variant 1 [GenBank NM_024302]: 5'-CTGCGGCAGTGT-
CATTGAATG-3' (forward), 5'-GGGCCCCGGAACCT-3'
(reverse), and 5'-CATCGACCCCCTTTGAAG-3' (probe).
2. Variant 2 [GenBank NM_032950]: 5'-CTGCGGCAGTGT-
CATTGAATG-3' (forward), 5'-CCCACGATGGTTGGTAT-
TCATATCA-3' (reverse), and 5'-
TTCTTCAAAGTGCAATCCGT-3' (probe).
Relative quantification of genes was performed using the ABI
Prism 7700 sequence detection system (Applied Biosystems,
Warrington, UK) in accordance with the manufacturer's proto-
col. PCR reactions contained 5 ng of reverse-transcribed RNA
(1 ng for 18S analyses), 50% TaqMan 2X Master Mix (Applied
Biosystems, Warrington, UK), 100 nM of each primer and 200
nM of probe in a total volume of 25 µl. Conditions for the PCR
reaction were as follows: 2 minutes at 50°C, 10 minutes at
95°C, 40 cycles of 15 seconds at 95°C, and 1 minute at 60°C.
The threshold cycle (CT), the cycle number at which signal is
detectable above the baseline, was transformed in two ways.
To gain an approximate comparison across all genes meas-
ured, amplification efficiency was assumed identical across all
primer sets and target gene expression was normalized to 18S
expression using a logarithmic transformation proportional to
normalized copy number (log102-∆CT), where ∆CT is CT(target
gene) – CT(18S) [30]. When comparing the expression of a
single gene across the sample groups, standard curves for
each gene were generated using the cDNA from one sample
and making twofold serial dilutions across an appropriate
range. Relative input amounts of template cDNA were then
calculated from CT using the standard curves; data are pre-
Figure 2
Comparative expression of ADAMTS genes in the fractured NOF (filled boxes) compared with OA (open boxes) hip (a) synovium and (b) cartilage Comparative expression of ADAMTS genes in the fractured NOF (filled boxes) compared with OA (open boxes) hip (a) synovium and (b) cartilage. 
The expression level of each gene was determined, as described in Materials and methods, and normalized to the level of 18S rRNA gene expres-
sion using ∆CT [CT(target gene) – CT(18S)]. The box-and-whisker plot shows median values, and each section represents a quartile of the data. 
Samples on or below the dotted line have CT(target gene) = 40 and are therefore not detectable (n.d.).Available online http://arthritis-research.com/content/8/4/R124
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sented as relative levels of mRNA normalized to 18S rRNA.
Statistical analyses between OA and fractured NOF samples
were performed using this latter method.
For comparison of expression levels between genes, cDNA for
18S, MMP13, MMP28 and ADAMTS16 was subcloned into
a plasmid vector. Serial dilutions of these plasmids, between
10-12 moles and 10-23 moles DNA, were used to create a
standard curve. This enabled CT to be converted into the
number of cDNA molecules and calculation of the ratio of tar-
get gene to 18S.
As a final quality control for the purified RNA samples, only
cDNA falling within ± 1.5 CT of the median value for 18S for
all samples were used in the downstream study. To ascertain
whether the amplification product was indeed that of the
desired target gene, products were subcloned and
sequenced. All primer and probe sets were shown to amplify
specific products from appropriate human tissue samples
[28,29].
Statistical analysis
Differences between control and OA groups were defined
using a two-sided Mann-Whitney U test; this nonparametric
test makes no prior assumption about the distribution of the
data. Correlations between genes were assessed using
Spearman's rank correlation.
Results
Expression of the MMP gene family
All MMP genes, with the exception of MMP20 (which we have
previously shown to be expressed neither in cartilage nor in
many other tissues), were profiled in synovium and cartilage
tissues. OA cartilage was compared with tissue from fractured
NOF, with results shown in Figure 1. MMP9 (P < 0.0001 and
P = 0.0204), MMP11 (P < 0.0001 and P = 0.0068), MMP13
(P < 0.0001 and P = 0.0037), MMP16 (P = 0.0014 and P =
0.036) and MMP28 (P = 0.0048 and P < 0.0001) were all
upregulated in OA, both in cartilage and in synovium (P values
represent cartilage and synovium, respectively). MMP10 (P <
0.0001 and P < 0.0001) was downregulated in both tissues
(P  values represent cartilage and synovium, respectively).
MMP2 (P < 0.0001), MMP8 (P = 0.0135), MMP15 (P =
0.003),  MMP17  (P  = 0.0146), MMP19  (P  < 0.0001),
MMP21 (P = 0.0007), MMP23 (P < 0.0001) and MMP24 (P
= 0.0212) were upregulated in OA cartilage, but no significant
change was seen in OA synovium. However, a trend towards
an increase of MMP24 (P = 0.0536) in OA synovium was
observed but did not reach statistical significance. MMP1 (P
= 0.0001), MMP3 (P < 0.0001) and MMP12 (P = 0.0146)
were downregulated in OA cartilage, but no significant change
was observed in OA synovium. MMP25 and MMP26 were not
detected in cartilage.
Expression of the ADAMTS gene family
All ADAMTS genes were profiled in synovium and cartilage
tissues with OA and compared with tissue from fractured NOF
(Figure 2). In both cartilage and synovium tissues, ADAMTS2
(P < 0.0001 and P = 0.009), ADAMTS10 (P = 0.048 and P
= 0.02) and ADAMTS16 (P < 0.0001 and P < 0.0001) were
upregulated, whereas ADAMTS1  (P  = 0.0011 and P  =
0.0143),  ADAMTS4  (P  = 0.0043 and P  < 0.0001),
ADAMTS5 (P = 0.0135 and P = 0.0109) and ADAMTS9 (P
< 0.0001 and P < 0.0001) were downregulated compared
with the NOF samples. In OA cartilage, ADAMTS3  (P  =
0.0017), ADAMTS7 (P = 0.0002), ADAMTS12 (P < 0.0001),
ADAMTS14  (P  < 0.0001), ADAMTS15  (P  = 0.045),
ADAMTS18 (P = 0.0033) and ADAMTS20 (P = 0.0014),
were upregulated, but no significant change was seen in syn-
ovium. In OA synovium, ADAMTS8 (P = 0.0017), ADAMTS13
(P = 0.0045) and ADAMTS17 (P < 0.0001) were upregu-
lated, but no significant change was seen in cartilage.
Figure 3
Comparative expression of TIMP genes in the fractured NOF (filled boxes) compared with OA (open boxes) hip synovium and cartilage Comparative expression of TIMP genes in the fractured NOF (filled boxes) compared with OA (open boxes) hip synovium and cartilage. The expres-
sion level of each gene was determined, as described in Materials and methods, and normalized to the level of 18S rRNA gene expression using 
∆CT [CT(target gene) – CT(18S)]. The box-and-whisker plot shows median values, and each section represents a quartile of the data.Arthritis Research & Therapy    Vol 8 No 4    Davidson et al.
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ADAMTS8 was not detected in cartilage tissue and no signif-
icant change in expression was seen in ADAMTS6  or
ADAMTS19 genes in either cartilage or synovium.
Expression of the TIMP gene family
All TIMP genes were profiled in synovium and cartilage tissues
with OA and compared with tissue from fractured NOF (Figure
3). In OA cartilage, TIMP1 (P < 0.0001) and TIMP4 (P =
0.0033) were downregulated. No change was seen in TIMP2
or TIMP3 levels. In OA synovium, TIMP2 (P < 0.0001) was
upregulated, but no significant changes were seen in TIMP1,
TIMP3 or TIMP4 levels.
Correlation of gene expression between tissues
For 11 OA and 13 NOF samples, cartilage and synovium
taken from the same joint was analysed. Although these sam-
ple numbers are small for correlation analysis, a number of
genes show a correlation in expression between tissues:
MMP9 (r = 0.584; P < 0.01), MMP10 (r = 0.645; P < 0.001),
MMP12 (r = -0.439; P < 0.05), MMP17 (r = 0.418; P < 0.05),
MMP23 (r = 0.411; P < 0.05), MMP28 (r = 0.412; P < 0.05),
ADAMTS4 (r = 0.521; P < 0.01), ADAMTS9 (r = 0.611; P <
0.002), and ADAMTS16 (r = 0.398; P = 0.054). Figure 4
shows the two most significant correlations.
Comparison of MMP13, MMP28 and ADAMTS16 
expression
In our previous work [26], the identification of MMP28 and
ADAMTS16 as genes significantly upregulated in OA carti-
lage raised the question of how their expression levels com-
pared with that of MMP13, the MMP pathognomic of collagen
destruction in OA. Hence, we subcloned cDNA for each gene
and used these to establish a standard curve of the absolute
number of molecules of cDNA against the CT value. Figure 5
shows that the median level of expression of MMP13  is
approximately 20-fold higher than that of MMP28 in cartilage
and approximately 1,500-fold higher than ADAMTS16. The
median level of MMP13 is similar in cartilage and synovium,
whereas MMP28 is expressed at an approximately eightfold
higher level and ADAMTS16 is expressed at an approximately
150-fold higher level in synovium compared with cartilage
(data not shown).
Expression of MMP28 splice variants
Two splice variants of MMP28  are listed on the database
[GenBank NM_024302 and NM_032950]. The longer mRNA
includes exon 8, which contains an in-frame stop codon, lead-
ing to a protein truncated in the C-terminal hemopexin-like
domain; the shorter mRNA excludes exon 8 and encodes a
protein with a complete C-terminal domain. Taqman primer/
probe sets were designed to distinguish between these vari-
ants and verify them against cloned cDNA. This demonstrated
that only the shorter mRNA (encoding the full-length protein)
was expressed at a detectable level in cartilage (data not
shown).
Discussion
This is the first study to profile the expression of all MMP,
ADAMTS and TIMP genes in synovium and compare tissue
from OA patients with those who have a fracture to the NOF.
Konttinen et al. had previously used conventional reverse-tran-
scriptase PCR to profile the expression of 16 MMPs in syn-
ovium (MMP1–3, MMP7-17 and MMP19), with induction of
MMP1, MMP9, MMP13, MMP14 and MMP15 in synovium
from rheumatoid arthritis compared with trauma controls [31].
Recent studies show that inflammatory changes in the OA
synovium are variable throughout the tissue [23,24]. This
might be expected to confound measurement of regulated
gene expression in this tissue because variation across the tis-
sue within a single joint would lead to greater variation in gene
expression within each patient group. This is borne out by our
study, in which more genes showed significant regulation
between OA and fractured NOF in cartilage than synovium.
Several studies have measured MMPs in synovium or synovial
fluid and demonstrated that levels of MMP-1 and MMP-3 are
elevated in rheumatoid arthritis (compared with OA or other
control groups, such as joint trauma; e.g. [32-36]). High
expression of a number of MMPs has been demonstrated in
rheumatoid pannus, suggesting a role mediating cartilage
destruction in RA (e.g. [31,37]). Indeed, levels of synovial fluid
MMP-1 and MMP-3 correlate to synovial hyperplasia [38].
Although levels of synovial fluid MMPs are generally raised in
RA compared with OA, the levels of at least MMP-1–3, MMP-
8, MMP-9 and TIMP-1 are reported to be raised in OA com-
pared with control, nonarthritic, synovial fluid (e.g. [39,40]).
In this study, the four most significantly upregulated genes (P
< 0.0001) in OA synovium compared with fracture of the NOF
are MMP28, ADAMTS16, ADAMTS17 and TIMP2. Interest-
ingly, we recently published the first report of MMP28 and
ADAMTS16 gene expression in cartilage and their upregula-
tion in OA [26]. Although these enzymes have no known func-
tion, the fact that their expression is switched on in at least two
tissues of the OA joint underlines their probable role in this dis-
ease. ADAMTS17 is another recently cloned ADAMTS family
member with unknown function and this is the first report of its
expression in synovium. TIMP-2 can inhibit the activity of all the
MMPs and the increase in expression in OA synovium might
represent an attempt to control proteolysis. The expression of
MMP13, the probable key collagenase in OA, is also upregu-
lated in OA synovium, in addition to cartilage.
MMP-1, MMP-2, MMP-9–11, MMP-13 and TIMP-2 are all
expressed in human growth plate hypertrophic chondrocytes
[41]. Interestingly, a significant subset of these (MMP2,
MMP9, MMP11, MMP13 and TIMP2) is upregulated in OA
cartilage.Available online http://arthritis-research.com/content/8/4/R124
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MMP-1 and MMP-3 are the most frequently measured
enzymes in RA, where correlations of synovial fluid or serum
levels to disease activity have been reported [36,39]. Our data
show that in synovium there is no difference in expression
between OA and fracture to the NOF, whereas in cartilage, as
we and others have previously reported, there is a significant
downregulation of expression in OA [26,42]. This might reflect
the late stage of the disease tissue in our study (see below),
or, for MMP-3, a maintenance role in cartilage metabolism. Our
data support the fact that MMP3 is a highly expressed gene in
synovium, as previously reported [37].
Other genes expressed at significantly higher levels in OA syn-
ovium compared with fracture to the NOF are MMP9, MMP11,
MMP16, ADAMTS8, ADAMTS10 and ADAMTS13, although
the absolute expression of ADAMTS8 is low. MMP-9 has pre-
viously been reported as elevated in RA synovium (e.g.
[31,38]) and in synovium and synovial fluid in a dog model of
OA [43]. Elevated MMP11 expression has also been previ-
ously reported in late-stage OA [42]. MMP16 expression has
been reported in synovium, but was not associated with dis-
ease [31], whereas ADAMTS8, ADAMTS10 and ADAMTS13
have not previously been described in synovium. ADAMTS-8
is capable of degrading aggrecan [44], although with lesser
catalytic efficiency compared with, for example, ADAMTS-4 or
ADAMTS-5.
The expression of MMP10 was the most significantly down-
regulated of any MMP in OA synovium compared with frac-
tured NOF. MMP10  expression has been previously
described in synovium, but its regulation has not been
described in disease [31]. MMP10 expression has also been
associated with the invasive potential of synovial fibroblasts in
both OA and RA [45].
We previously reported that the expression of ADAMTS4,
ADAMTS5 and ADAMTS9, all aggrecanases, was downregu-
lated in OA cartilage compared with fractured NOF [26].
These genes, particularly ADAMTS4 and ADAMTS9, are also
downregulated in OA synovium. This could reflect a role for
aggrecanases in the earlier phases of OA, but similar expres-
sion patterns in cartilage and synovium could also suggest a
role for the synovium in aggrecan turnover and breakdown.
Synovium has been shown to express soluble aggrecanase
activity [46], and ADAMTS-5 has been localized to human syn-
ovium [47].
A comparison of the expression patterns of MMP, ADAMTS
and TIMP genes in cartilage in this study with those in our pre-
vious report shows predominantly similar data. Overall, a
greater number of genes were regulated between OA and
fractured NOF samples in the current study. This might reflect
differences in the actual patient groups in each study or the
rapidity of tissue dissection and processing. Genes induced in
OA with weak significance in the current study, MMP17,
Figure 5
Comparison of MMP13, MMP28 and ADAMTS16 expression levels in  cartilage Comparison of MMP13, MMP28 and ADAMTS16 expression levels in 
cartilage. Expression of each gene was quantified against standard 
curves constructed using purified cDNA and normalized to 18S expres-
sion, which was similarly quantified. Median values are marked.
Figure 4
Correlation analysis of gene expression in cartilage compared with syn- ovium Correlation analysis of gene expression in cartilage compared with syn-
ovium. Correlation plots for (a) MMP10 and (b) ADAMTS9 expression 
in cartilage and synovium taken from the same joint. Correlation coeffi-
cients are as follows: MMP10, r = 0.645 (P = 0.0006); and 
ADAMTS9, r = 0.590 (P = 0.0024).Arthritis Research & Therapy    Vol 8 No 4    Davidson et al.
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MMP24 and ADAMTS10, all show a trend towards induction
in our previous cohort but did not reach significance. The
same is true for MMP12,  MMP15  and  ADAMTS3.
ADAMTS15 showed upregulation in OA in the current study
at P < 0.05 and similarly significant downregulation in our pre-
vious study. This might represent variation because of multiple
testing. More difficult to explain are the significantly upregu-
lated genes in OA in the current study, MMP21 (P < 0.001),
MMP19  (P  < 0.0001) and MMP23  (P  < 0.0001); these
genes showed no significant difference in our earlier cohort.
Where genes are annotated as 'not detected' (Figures 1, 2, 3
and [26], these might not be expressed at all in the tissue or
the median CT is 40, with a few samples showing a low level
of expression.
For  MMP9,  MMP10,  MMP12,  MMP17, MMP23,  MMP28,
ADAMTS4, and ADAMTS9, there is a significant correlation
between expression levels in the synovium and cartilage. This
presumably reflects the fact that these tissues are exposed to
a similar environment in terms of growth factors and cytokines.
For genes where expression between the two tissues does not
correlate, there must therefore be other factors driving expres-
sion, such as mechanical load, oxidative stress and cell-matrix
interaction.
To resolve previously raised questions, we used plasmid
cDNA for MMP13,  MMP28  and  ADAMTS16  to construct
standard curves for these genes. This demonstrated that
MMP13 was the most abundant mRNA of the three genes. It
remains impossible to speculate about their relative impor-
Table 1
Genes with changing expression levels in cartilage or synovium when comparing OA with fracture to the NOF
P value Cartilage Synovium
Up Down Up Down
<0.05 MMP8 ADAMTS5 MMP9 ADAMTS1
MMP17 MMP16 ADAMTS5
MMP24 ADAMTS10
ADAMTS10
ADAMTS15
<0.01 MMP15 MMP12 MMP11
MMP16 ADAMTS1 MMP13
MMP28 ADAMTS4 ADAMTS2
ADAMTS3 TIMP4 ADAMTS8
ADAMTS18 ADAMTS13
ADAMTS20
<0.001 MMP21
ADAMTS7
<0.0001 MMP2 MMP1 MMP28 MMP10
MMP9 MMP3 ADAMTS16 ADAMTS4
MMP11 MMP10 ADAMTS17 ADAMTS9
MMP13 ADAMTS9 TIMP2
MMP19 TIMP1
MMP23
ADAMTS2
ADAMTS12
ADAMTS14
ADAMTS16Available online http://arthritis-research.com/content/8/4/R124
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tance because the substrates, and therefore the specific activ-
ities of MMP-28 and ADAMTS-16, are unknown.
Conclusion
This study is the most comprehensive analysis of the metzincin
family of proteinases in the joint to date and has identified sev-
eral proteinase genes not previously reported to be expressed
or regulated in synovium. Future work will focus on the function
of key genes. The data also show coordinate regulation of a
subset of genes throughout the synovium and cartilage that
might inform analyses of regulatory pathways and transcription
factors.
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